WuXi Biologics has initiated the construction of a new microbial manufacturing site in the Wenjiang district of Chengdu. This facility, featuring a 15,000L fermenter with an expansion potential to 60,000L, is set to produce 80 to 110 drug substance batches annually. It will also house China's first dual-chamber lyophilization production line and a vial filling line, boasting a drug product manufacturing capacity exceeding 10 million vials per year. The site will utilize WuXi Biologics' EffiXTM microbial expression platform, which promises high yield, consistent quality, and superior stability and scalability. The facilities are designed with advanced automated systems to ensure regulatory compliance and operational efficiency, alongside a strong focus on energy conservation and sustainability. This expansion positions WuXi Biologics to meet the increasing global demand for microbial products and advance the development of next-generation therapies.